-
Company Profile
BiondVax Pharmaceuticals Ltd – Company Profile
Scinai Immunotherapeutics Ltd (Scinai), formerly BiondVax Pharmaceuticals Ltd., is a biopharmaceutical company that develops, manufactures and commercializes biological products for the treatment of infectious and autoimmune diseases. Scinai’s alpaca-derived nanosized antibodies (NanoAbs) development pipeline includes anti‑interleukin 17 (anti-IL-17) NanoAbs for the treatment of autoimmune diseases such as psoriasis, psoriatic arthritis, atopic dermatitis and hidradenitis suppurative (HS); RBD for Covid 19 therapeutic and prophylactic; anti-IL-4Ra, IL-13 and anti-TSLP for the treatment of asthma; and anti-Ang-2 and anti-VEGF for the treatment of...
Add to Basket -
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – M-001
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry M-001 Drug Details M-001 is under development for the prevention of multiple strains of...
-
Product Insights
Psoriatic Arthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis. Symptoms include swollen fingers and toes, foot pain, and lower back pain. Risk factors include age, family history, and psoriasis. Treatment includes NSAIDs, immunosuppressants, and surgery. The Psoriatic Arthritis pipeline drugs market research report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The...
-
Product Insights
Influenza A Virus, H5N1 Subtype Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Influenza A Virus, H5N1 Subtype Infections pipeline market report provides a comprehensive overview on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in...
-
Product Insights
Influenza A Virus, H3N2 Subtype Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
H3N2 infections are caused by variant H3N2 virus which is an influenza virus. Symptoms include cough, sore throat, runny or stuffy nose, chills, nausea, vomiting, and/or diarrhea. Risk factors include age, chronic medical conditions like asthma, diabetes, heart disease, weakened immune systems, and neurological or neurodevelopment conditions. Treatment includes antiviral medications and antibiotics. The Influenza A Virus, H3N2 - drugs in development research report provides a comprehensive overview on the therapeutics under development for Influenza A Virus, H3N2, complete with...